PipelineReview.com6h
LTZ Therapeutics Announces FDA Clearance of IND Application to Initiate Trial of First-in-Class Myeloid Engager Immunotherapy, LTZ-301
REDWOOD CITY, CA, USA & SHENZHEN, China I4, 2025 I LTZ Therapeutics, an immunotherapy-focused biotech company, today announced that the U.S.
PipelineReview.com6h
Vicero’s Novel Cancer Immunotherapy Demonstrates Dual-Target Precision with Improved Safety Profile
Late-breaker poster presentation at the inaugural AACR IO underscores potential of VCR-036, a novel PD-1/CTLA-4 VHH antibody for treatment of solid tumors ...
PipelineReview.com9h
Celltrion Receives EC Approval for Avtozma® (CT-P47), a Biosimilar to RoActemra® (tocilizumab)
INCHEON, South Korea I February 23, 2025 I Celltrion today announced that the European Commission (EC) has granted marketing authorization for Avtozma® ...
PipelineReview.com8h
ElevateBio Announces Compelling Preclinical Data Demonstrating the Potential of LETI-101 as a Treatment for Huntington’s Disease
LETI-101 has demonstrated therapeutically relevant reductions of mutant huntingtin (HTT) protein, exceeding 80%, while preserving essential wild-type ...
PipelineReview.com9h
Halda Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating HLD-0915 in Metastatic Castration-Resistant Prostate Cancer
First-in-human clinical trial to evaluate safety and tolerability of a new class of small molecule medicines for the treatment of cancer, RIPTAC™ therapeutics ...
PipelineReview.com8h
Biocon Biologics Launches Yesintek™ (ustekinumab-kfce) Biosimilar to Stelara® in the United States
BRIDGEWATER, NJ, USA and BENGALURU, India I4, 2025 I Biocon Biologics Ltd. (BBL), a fully integrated global biosimilars company and ...
PipelineReview.com9h
Samsung Bioepis Announces US Launch of PYZCHIVA® (ustekinumab-ttwe), Biosimilar to Stelara
INCHEON, Korea I February 24, 2025 I Samsung Bioepis Co., Ltd. today announced that PYZCHIVA® (ustekinumab-ttwe), a biosimilar to Stelara (ustekinumab), is ...
PipelineReview.com2d
Teva and Alvotech Announce SELARSDI™ (ustekinumab-aekn) Injection Now Available in the U.S.
REYKJAVIK, Iceland and PARSIPPANY, NJ, USA I1, 2025 I Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: ...
PipelineReview.com2d
Boehringer Ingelheim and partners start clinical development of a first-in-class, inhaled gene therapy for people with cystic fibrosis
INGELHEIM, Germany I, 2025 I Boehringer Ingelheim, IP Group, the UK Respiratory Gene Therapy Consortium (GTC)∗ and OXB,ŧ today announce the start ...
PipelineReview.com2d
Gilead’s Seladelpar Granted Conditional European Marketing Authorization for the Treatment of Primary Biliary Cholangitis
Approved, Seladelpar Can Provide an Important Treatment Option for People Living With the Rare Liver Disease in the European Economic Area – ...
PipelineReview.com2d
Myris Therapeutics is Developing Ultra-High DAR ADCs to Enable Novel Precision Medicine Treatments for Cancer
PITTSBURGH, PA, USA I February 20, 2025 I Myris Therapeutics™ emerged from stealth today to announce its strategic focus. Myris, formerly known as ...
PipelineReview.com2d
Estrella Immunopharma Completes First Dose Cohort in STARLIGHT-1 Trial and Receives Approval to Initiate Higher Dose Cohort
EMERYVILLE, CA, USA I1, 2025 I Estrella Immunopharma, Inc. (NASDAQ: ESLA, ESLAW) (“Estrella” or the “Company”), a clinical stage biopharmaceutical ...